Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
In Vivo
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
In Vivo

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Preoperative C-Reactive Protein/Albumin Ratio as a Predictive Factor for Gallbladder Carcinoma

MASASHI UTSUMI, HIDEKI AOKI, SEICHI NAGAHISA, SEITARO NISHIMURA, YUTA UNE, YUJI KIMURA, MEGUMI WATANABE, FUMITAKA TANIGUCHI, TAKASHI ARATA, KOH KATSUDA and KOHJI TANAKAYA
In Vivo July 2020, 34 (4) 1901-1908; DOI: https://doi.org/10.21873/invivo.11986
MASASHI UTSUMI
Department of Surgery, National Hospital Organization, Iwakuni Clinical Center, Yamaguchi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: masashi11232001@yahoo.co.jp
HIDEKI AOKI
Department of Surgery, National Hospital Organization, Iwakuni Clinical Center, Yamaguchi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SEICHI NAGAHISA
Department of Surgery, National Hospital Organization, Iwakuni Clinical Center, Yamaguchi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SEITARO NISHIMURA
Department of Surgery, National Hospital Organization, Iwakuni Clinical Center, Yamaguchi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUTA UNE
Department of Surgery, National Hospital Organization, Iwakuni Clinical Center, Yamaguchi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUJI KIMURA
Department of Surgery, National Hospital Organization, Iwakuni Clinical Center, Yamaguchi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MEGUMI WATANABE
Department of Surgery, National Hospital Organization, Iwakuni Clinical Center, Yamaguchi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FUMITAKA TANIGUCHI
Department of Surgery, National Hospital Organization, Iwakuni Clinical Center, Yamaguchi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKASHI ARATA
Department of Surgery, National Hospital Organization, Iwakuni Clinical Center, Yamaguchi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KOH KATSUDA
Department of Surgery, National Hospital Organization, Iwakuni Clinical Center, Yamaguchi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KOHJI TANAKAYA
Department of Surgery, National Hospital Organization, Iwakuni Clinical Center, Yamaguchi, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: The C-reactive protein (CRP) to albumin ratio (CAR) is associated with outcomes in patients with sepsis. We aimed to evaluate the significance of preoperative CAR in therapeutic outcomes after gallbladder carcinoma (GBC) resection. Patients and Methods: Fifty-three patients who underwent surgical resection for GBC between January 2008 and September 2019 were enrolled. We retrospectively investigated the relation between preoperative CAR and overall and disease-free survival. Results: The optimal cut-off CAR was 0.07. Multivariate analysis showed that i) R1 or R2 resection (p=0.033), ii) advanced tumor stage (p=0.047), iii) CAR≥0.07 (p=0.011), and iv) postoperative complications (p=0.028) were significant independent predictors of overall survival; moreover, higher carbohydrate antigen levels (p=0.036) and R1 or R2 resection (p<0.001) were significant independent predictors of disease-free survival. Conclusion: Preoperative CAR may be a significant independent predictor of long-term outcomes after GBC resection.

  • C-reactive protein to albumin ratio
  • gallbladder carcinoma
  • Inflammation-based prognostic score

Gallbladder carcinoma (GBC) is relatively rarer compared to gastrointestinal carcinoma; however, its incidence is increasing worldwide, and it is considered the most common malignant biliary neoplasm and the seventh-most common type of gastrointestinal cancer (1). Curative resection is the only effective treatment for GBC; however, it is characterized by easy local invasion and lymph node metastasis (2). Most patients with GBC have progressed to the late stage at the time of diagnosis (3). The recurrence rate is high, and GBC is insensitive to radiotherapy and chemotherapy (4), thus, it has an extremely poor prognosis. The reported mean survival for patients with GBC ranges from 5.2 to 24.4 months (2-5). For all these reasons, investigating the prognostic factors for GBC is especially important.

There is increasing evidence that the systematic inflammatory response plays an important role in the development of various types of malignancy (6,7). The preoperative systematic inflammation, represented by i) the Glasgow prognostic score (GPS) (8), ii) the neutrophil-to-lymphocyte ratio (NLR) (9), iii) the platelet-to-lymphocyte ratio (PLR) (9), and iv) the prognostic nutritional index (PNI) (10) have all been reported to predict cancer-specific survival of GBC. We know that the GPS is based on the circulating levels of two acute phase proteins, i) C-reactive protein (CRP) and ii) albumin. Fairclough E et al. have established the CRP to albumin ratio (CAR), a novel inflammation-based prognostic score based on these two factors, to identify patients with serious illness on acute medical admission, and have reported that it is associated with poor outcomes in patients with sepsis (11, 12).

Recently, the prognostic ability of CAR has been reported in patients with i) hepatocellular carcinoma (13), and ii) gastric (14), iii) ovarian (15), iv) colorectal (16), v) esophageal (17), and vi) pancreatic cancers (18, 19). In fact, elevated preoperative CAR has been associated with poor survival in patients with the aforementioned cancer types. To our knowledge, the prognostic value of CAR has not been reported in patients with GBC. Therefore, in this study, we retrospectively investigated the relation between preoperative CAR and the overall survival and disease-free survival rates after surgical GBC resection. Moreover, we compared the predictive values of CAR, GPS, NLR, PLR, and PNI.

Patients and Methods

The study protocol was approved by the Human Ethics Review Committee of Iwakuni Clinical Center (number: 0183). The study was conducted in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments. Informed consent was obtained from all individual participants included in the study (20).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Patient characteristics.

Between January 2008 and September 2019, 53 patients with GBC underwent surgical resection at the Iwakuni Clinical Center. Clinical data, tumor characteristics, and survival outcomes were retrospectively reviewed. All participants provided a written informed consent to keep their data in the hospital database, prior to data collection.

We investigated the ways in which clinicopathological variables, such as sex, age, body mass index, associated diseases (hypertension, diabetes, cardiac disease, and stroke), the American Society of Anesthesiologists physical status score, surgical procedure, blood loss, duration of operation, tumor stage according to the Union for International Cancer Control classification, and status of the CAR are related (21, 22). We also assessed the overall and disease-free survival rates after surgery using univariate and multivariate analyses by dividing all patients into the high and low CAR groups. Furthermore, we compared the predictive values of CAR, GPS, NLR, PLR, and PNI.

Definition of the inflammation-based prognostic system. Peripheral venous blood samples were collected within 2 weeks before surgery, used for the detection of granulocyte, leukocyte, platelet, albumin, CRP, carbohydrate antigen (CA19-9), and carcinoembryonic antigen (CEA) levels. From these results we calculated CAR, GPS, NLR, and PLR. CAR was calculated by dividing serum CRP (mg/dl) by serum albumin levels (g/l). GPS was calculated as follows: i) patients with an elevated CRP level (>1.0 mg/dl) and hypoalbuminemia (<3.5 g/dl) were scored as 2, ii) those who only had one of these biochemical abnormalities as 1, and those who had no such abnormalities were evaluated with a score of 0 (23). NLR and PLR were calculated by dividing neutrophil and platelet counts by lymphocyte count, respectively (19,20). PNI was calculated according to the following formula: 10×serum albumin (g/dl)+0.05×total lymphocyte count (per mm3).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Comparison of areas under the receiver operating characteristic curves for outcome prediction among the five inflammation-based markers. NLR: Neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio; PNI: prognostic nutrient index; CAR: C-reactive protein to albumin ratio; GPS: Glasgow prognostic score.

Surgical strategy and follow-up. We applied evidence-based clinical practice guidelines for the treatment of GBC (26, 27). Based on preoperative imaging studies and clinical data, hepatectomy was indicated only in cases in which sufficient hepatic function would have been conserved post-surgery. According to incidental GBC, we used reported treatment strategies (28). Following surgery, all patients were carefully monitored. Tumor marker levels from serum measurements, ultrasonography, and computed tomography were conducted every 3 months. The follow-up period ended in the last follow-up visit (February 2020) or in case of death. At the time of manuscript preparation, the median follow-up time of surviving patients was 34 (range=1-130) months.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Univariate and multivariate analyses of clinicopathological variables in relation to overall survival after resection of gallbladder carcinoma.

Complications were defined according to the method described by Clavien et al. (29). In this study, postoperative complications were defined as complications that were grade 2 or higher, while postoperative mortality was defined as any death incident occurring within 30 days post-surgery.

Statistical analysis. Data are expressed as mean±standard deviation (SD). Univariate analysis was performed using the Mann-Whitney U and the Chi-square tests. Diagnostic accuracy was determined by the area under the receiver operating characteristic curve (ROC). The optimal cut-off values of CAR, NLR, GPS, PLR, and PNI were determined by maximizing the Youden index (sensitivity+ specificity−1) (30). The Kaplan-Meier method was used to analyze the overall and disease-free survival rates while the log-rank test was used to compare differences between the subgroups. Univariate and multivariate analyses were performed for the prognostic factors using the Cox proportional hazard model, as significant different variables analyzed by the univariate analysis were further analyzed by the multiple Cox proportional hazards model. The statistical significance level was set at p<0.05 in all analyses. Statistical analysis was performed using JMP version 9 (SAS Institute, Cary, NC, USA).

Results

Patient characteristics. Fifty-three patients were enrolled in this study [mean age=73.0±11.92 years (range=38-95), sex=30 men and 23 women]. Patient characteristics are outlined in Table I. Operative procedures consisted of: i) cholecystectomy (13 patients), ii) liver bed resection (6 patients), iii) hepatic resection of segments 4b and 5 (26 patients), iv) extended right lobectomy (5 patients), v) hepatopancreaticoduodenectomy (3 patients), and vi) pancreaticoduodenectomy (one patient). Postoperative complications developed in 20 of 51 patients; these included: i) bile leakage (10 patients), ii) surgical site infection (two patients), iii) pancreatic fistula (two patients), iv) abdominal abscess (two patients), v) ileus (two patients), vi) chylous ascites (one patient), and vii) acute respiratory distress syndrome (one patient).

ROC analysis. Using the overall survival rate as an endpoint, the optimal cut-off value for inflammation-based markers was determined using the area under the curve (AUC) of ROC curves: i) CAR=0.07 (AUC=0.823), ii) PNI=47.9 (AUC=0.771), iii) GPS=1 (AUC=0.751), iv) NLR=3.72 (AUC=0.661), and v) PLR=0.13 (AUC=0.596). The CAR value was the highest (statistically significant) among the inflammation-based markers (Figure 1).

Univariate and multivariate analyses of the clinicopathological variables in relation to overall survival after surgical GBC resection. The 1-, 3-, and 5-year overall survival rates were 84.1, 65.4, and 57.6%, respectively. Table II shows the relationship between the clinicopathological variables and the overall survival rates following surgical GBC resection. In the univariate analysis, the overall survival was significantly worse in patients with increased CEA levels (p<0.001), CA19-9 (p<0.001), R1 or R2 resection (p<0.001), tumor stage 3 or 4 (p<0.001), CAR≥0.07 (p<0.001, Figure 2a), GPS 1 or 2 (p<0.001), NLR≥3.72 (p<0.001), PNI<47.9 (p<0.001), and postoperative complications (p=0.002). In the multivariate analysis, R1 or R2 resection (p=0.033), tumor stage 3 or 4 (p=0.047), CAR≥0.07 (p=0.011), and postoperative complications (p=0.028) were independent and significant predictors of overall survival.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Relationship of the C-reactive protein to albumin ratio with overall survival (a) and disease-free survival (b). NLR: Neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio; PNI: prognostic nutrient index; CAR: C-reactive protein to albumin ratio; GPS: Glasgow prognostic score.

Univariate and multivariate analyses of the clinicopathological variables in relation to disease-free survival following surgical GBC resection. Table III shows the relationship between the clinicopathological variables and the disease-free survival following surgical GBC resection. In the univariate analysis, disease-free survival was significantly worse in patients with higher CEA levels (p=0.006), CA19-9 (p<0.001), R1 or R2 resection (p<0.001), tumor stage 3 or 4 (p<0.001), CAR≥0.07 (p<0.001, Figure 2b), GPS 1 or 2 (p<0.001), NLR≥3.72 (p=0.001), PNI<47.9 (p=0.002), and postoperative complications (p=0.008). In the multivariate analysis, higher levels of CA19-9 (p=0.036) and R1 or R2 resection (p<0.001) were independent and significant predictors of disease-free survival.

Association between the clinicopathologic variables and the CAR. Table IV shows the relationship between the clinicopathologic variables and the CAR. Patients with CAR≥0.07 have i) significantly longer duration of operation (p<0.001), ii) greater blood loss (p<0.001), iii) more advanced tumor stage (p=0.014), iv) higher CEA levels (p=0.025), and v) more postoperative complications (p<0.001) compared to those with CAR<0.07. Additionally, the CAR was associated with other inflammatory markers, including GPS (p<0.001), NLR (p<0.001), PLR (p=0.003), and PNI (p<0.001).

Discussion

This study demonstrated that non-curative resection, advanced tumor stage, elevated CAR, and postoperative complications were independent prognostic factors of poor survival following GBC resection. Elevated CA19-9 and non-curative resection were independent predictors of worse recurrence-free survival. Moreover, only the CAR was evaluated as an independent preoperative prognostic factor. Conversely, the other established inflammation-based prognostic scores in the multivariate analysis, such as GPS, NLR, PLR, and PNI, were poor independent prognostic factors. Consequently, we compared CAR's prognostic ability to the other inflammation-based prognostic scores, and found that in the context of GBC, the AUC of the CAR was superior to other scores in terms of predictive accuracy. These results are consistent with previous studies identifying the CAR as an outcome predictor of hepatocellular carcinoma (13), as well as of gastric (14), ovarian (15), colorectal (16), and pancreatic cancer (18, 19).

Furthermore, we noted that an increased CAR was significantly correlated with i) an advanced stage, ii) increased CEA, iii) longer duration of operation, iv) greater blood loss, and v) postoperative complications, suggesting that it may be correlated with more aggressive surgery and disease phenotype.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Univariate and multivariate analyses of clinicopathological variables in relation to disease-free survival after resection of gallbladder carcinoma.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table IV.

Univariate and multivariate analyses of clinicopathological variables in relation to C-reactive protein to albumin ratio.

The association between inflammation and cancer is based on the observation that tumors often arise on chronic inflammation sites and that inflammatory cells are present in biopsied samples collected from tumor tissues (31). In the case of GBC, chronic cholecystitis resulting from gallbladder stones or bacterial infection is thought to be a major oncogenic driver (32). Moreover, recent clinical and laboratory studies have indicated that inflammation is closely related to cancer progression and metastasis, and an inflammatory microenvironment has even been proposed as the seventh hallmark of cancer (33-35). Therefore, inflammation markers might predict the prognosis of various cancers, including GBC.

Currently, the correlational mechanism between the CAR and cancer-specific survival remains unclear. Elevated serum CRP levels reflect a non-specific inflammatory response to tumor necrosis or local tissue damage, and indicate a favorable environment for the establishment and growth of distant metastasis (36). In this study, patients with advanced tumor stage had an elevated CAR, potentially reflecting these factors. Xavier et al. have reported that Serum CRP inhibits apoptosis of cancer cells in a myeloma setting to determine whether CRP affects tumor cell growth and survival (37). Fondevila et al. have reported that serum levels of vascular endothelial growth factors (angiogenic factors) increase in the presence of elevated serum CRP concentration (38).

In addition, hypoalbuminemia is often observed in patients with advanced cancer and is regarded as a marker of malnutrition (39). Also, serum albumin participates in the systemic inflammatory response and its reduced levels are associated with poor long-term survival in patients with various cancers (40).

The CAR may reflect a systemic inflammatory response and the progressive nutritional decline, resulting in poor survival. Perioperative nutritional support was recommended to improve the nutritional status in patients with hepatobiliary-pancreatic carcinoma, as there was a high prevalence of malnutrition (41). Indeed, preoperative immunonutrition has been reported to suppress the perioperative inflammatory response (42). Further investigation to evaluate the relationship between immunonutrition and this inflammatory-based prognostic score is important to improve the management of patients with GBC.

To the best of our knowledge, this is the first study to investigate whether the CAR is useful for predicting postoperative outcomes in GBC. Survival following surgical resection for patients with GBC greatly depends on disease stage and whether curative resection is achieved; however, these can only be properly evaluated postoperatively. Our results suggest that the preoperative CAR might potentially serve as a clinically valuable marker in patients with GBC. The CAR has the advantage of being easily measured, routinely available, and well-standardized. Moreover, an increased CAR might be correlated with a more aggressive form of disease, thereby making it possible to use it for screening a subset of patients with bad prognosis who require intense treatment. Additionally, the CAR displayed an improved prognostic ability compared to the other inflammation-based scoring systems and may be a complementary factor for defining tumor stage in predicting survival in patients with GBC.

Our study had limitations, as it was a retrospective single-centre study with a small sample size. Prospective cohort studies in multiple institutions should be performed to confirm these results.

In conclusion, our study showed that the CAR may be an independent and significant indicator of poor long-term outcome in patients with GBC following surgery.\

Footnotes

  • Authors' Contributions

    MU, HA, SN, SN, YU, YK, MW, FT, TA, KK and KT designed the study. HA, MU and YK treated and observed the patients. MU prepared the manuscript and performed the literature search. HA corrected and revised the manuscript. All Authors read and approved the final manuscript.

  • This article is freely accessible online.

  • Conflicts of Interest

    The Authors declare that they have no conflicts of interest.

  • Received March 13, 2020.
  • Revision received April 6, 2020.
  • Accepted April 8, 2020.
  • Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

References

  1. ↵
    1. Donohue JH,
    2. Stewart AK,
    3. Menck HR
    : The National Cancer Data Base report on carcinoma of the gallbladder, 1989-1995. Cancer 83(12): 2618-2628, 1998. PMID: 9874470. DOI: 10.1002/(sici)1097-0142(19981215)83:12<2618::aid-cncr29>3.0.co;2-h
    OpenUrlCrossRefPubMed
  2. ↵
    1. Butte JM,
    2. Matsuo K,
    3. Gonen M,
    4. D'Angelica MI,
    5. Waugh E,
    6. Allen PJ,
    7. Fong Y,
    8. DeMatteo RP,
    9. Blumgart L,
    10. Endo I,
    11. De La Fuente H,
    12. Jarnagin WR
    : Gallbladder cancer: differences in presentation, surgical treatment, and survival in patients treated at centers in three countries. J Am Coll Surg 212(1): 50-61, 2011. PMID: 21075015. DOI: 10.1016/j.jamcollsurg.2010.09.009
    OpenUrlPubMed
  3. ↵
    1. Miller G,
    2. Jarnagin WR
    : Gallbladder carcinoma. Eur J Surg Oncol 34(3): 306-312, 2008. PMID:17964753. DOI: 10.1016/j.ejso.2007.07.206
    OpenUrlCrossRefPubMed
  4. ↵
    1. Bartlett DL,
    2. Fong Y,
    3. Fortner JG,
    4. Brennan MF,
    5. Blumgart LH
    : Long-term results after resection for gallbladder cancer. Implications for staging and management. Ann Surg 224(5): 639-646, 1996. PMID: 20495633. DOI: 10.1111/j.1477-2574. 2009.00108.x
    OpenUrlCrossRefPubMed
  5. ↵
    1. Cziupka K,
    2. Partecke LI,
    3. Mirow L,
    4. Heidecke CD,
    5. Emde C,
    6. Hoffmann W,
    7. Siewert U,
    8. van den Berg N,
    9. von Bernstorff W,
    10. Stier A
    : Outcomes and prognostic factors in gallbladder cancer: a single-centre experience. Langenbecks Arch Surg 397(6): 899-907, 2012. PMID: 22454256. DOI: 10.1007/s00423-012-0950-8
    OpenUrlPubMed
  6. ↵
    1. Mantovani A,
    2. Allavena P,
    3. Sica A,
    4. Balkwill F
    : Cancer-related inflammation. Nature 454(7203): 436-444, 2008. PMID: 18650914. DOI: 10.1038/nature07205
    OpenUrlCrossRefPubMed
  7. ↵
    1. Pages F,
    2. Galon J,
    3. Dieu-Nosjean MC,
    4. Tartour E,
    5. Sautès-Fridman C,
    6. Fridman WH
    : Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 29(8): 1093-1102, 2010. PMID: 19946335. DOI: 10.1038/onc. 2009.416
    OpenUrlCrossRefPubMed
  8. ↵
    1. Shiba H,
    2. Misawa T,
    3. Fujiwara Y,
    4. Futagawa Y,
    5. Furukawa K,
    6. Haruki K,
    7. Iwase R,
    8. Iida T,
    9. Yanaga K
    : Glasgow prognostic score predicts outcome after surgical resection of gallbladder cancer. World J Surg 39(3): 753-758, 2015. PMID: 25348884. DOI: 10.1007/s00268-014-2844-0
    OpenUrlPubMed
  9. ↵
    1. Zhang Y,
    2. Jiang C,
    3. Li J,
    4. Sun J,
    5. Qu X
    : Prognostic significance of preoperative neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in patients with gallbladder carcinoma. Clin Transl Oncol 17(10): 810-818, 2015. PMID: 26077119. DOI: 10.1007/s12094-015-1310-2
    OpenUrl
  10. ↵
    1. Deng Y,
    2. Pang Q,
    3. Bi JB,
    4. Zhang X,
    5. Zhang LQ,
    6. Zhou YY,
    7. Miao RC,
    8. Chen W,
    9. Qu K,
    10. Liu C
    : A promising prediction model for survival in gallbladder carcinoma patients: pretreatment prognostic nutrient index. Tumour Biol, 2016. PMID: 27722987. DOI: 10.1007/s13277-016-5396-0
  11. ↵
    1. Fairclough E,
    2. Cairns E,
    3. Hamilton J,
    4. Kelly C
    : Evaluation of a modified early warning system for acute medical admissions and comparison with C-reactive protein/albumin ratio as a predictor of patient outcome. Clin Med (Lond) 9(1): 30-33, 2009. PMID: 23555017. DOI: 10.1371/journal.pone. 0059321
    OpenUrl
  12. ↵
    1. Ranzani OT,
    2. Zampieri FG,
    3. Forte DN,
    4. Azevedo LC,
    5. Park M
    : C-reactive protein/albumin ratio predicts 90-day mortality of septic patients. PloS One 8(3): e59321, 2013. PMID: 23555017. DOI: 10.1371/journal.pone.0059321
    OpenUrlCrossRefPubMed
  13. ↵
    1. Kinoshita A,
    2. Onoda H,
    3. Imai N,
    4. Iwaku A,
    5. Oishi M,
    6. Tanaka K,
    7. Fushiya N,
    8. Koike K,
    9. Nishino H,
    10. Matsushima M
    : The C-reactive protein/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma. Ann Surg Oncol 22(3): 803-810, 2015. PMID: 25190127. DOI: 10.1245/s10434-014-4048-0
    OpenUrlCrossRefPubMed
  14. ↵
    1. Liu X,
    2. Sun X,
    3. Liu J,
    4. Kong P,
    5. Chen S,
    6. Zhan Y,
    7. Xu D
    : Preoperative C-reactive protein/albumin ratio predicts prognosis of patients after curative resection for gastric cancer. Transl Oncol 8(4): 339-345, 2015. PMID: 26310380. DOI: 10.1245/s10434-014-4048-0.
    OpenUrl
  15. ↵
    1. Liu Y,
    2. Chen S,
    3. Zheng C,
    4. Ding M,
    5. Zhang L,
    6. Wang L,
    7. Xie M,
    8. Zhou J
    : The prognostic value of the preoperative c-reactive protein/albumin ratio in ovarian cancer. BMC Cancer 17(1): 285, 2017. PMID: 28431566. DOI: 10.1186/s12885-017-3220-x
    OpenUrl
  16. ↵
    1. Shibutani M,
    2. Maeda K,
    3. Nagahara H,
    4. Iseki Y,
    5. Ikeya T,
    6. Hirakawa K
    : Prognostic significance of the preoperative ratio of C-reactive protein to albumin in patients with colorectal cancer. Anticancer Res 36(3): 995-1001, 2016. PMID: 26976989.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Sakai M,
    2. Sohda M,
    3. Saito H,
    4. Ubukata Y,
    5. Nakazawa N,
    6. Kuriyama K,
    7. Hara K,
    8. Sano A,
    9. Ogata K,
    10. Yokobori T,
    11. Shirabe K,
    12. Saeki H
    : Comparative analysis of immunoinflammatory and nutritional measures in surgically resected esophageal cancer: A single-center retrospective study. In Vivo 34(2): 881-887, 2020. PMID: 32111799. DOI: 10.21873/invivo.11853
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Haruki K,
    2. Shiba H,
    3. Shirai Y,
    4. Horiuchi T,
    5. Iwase R,
    6. Fujiwara Y,
    7. Furukawa K,
    8. Misawa T,
    9. Yanaga K
    : The C-reactive protein to albumin ratio predicts long-term outcomes in patients with pancreatic cancer after pancreatic resection. World J Surg 40(9): 2254-2260, 2016. PMID: 26956901. DOI: 10.1007/s00268-016-3491-4
    OpenUrlCrossRefPubMed
  19. ↵
    1. Vujic J,
    2. Marsoner K,
    3. Wienerroither V,
    4. Mischinger HJ,
    5. Kornprat P
    : The predictive value of the crp-to-albumin ratio for patients with pancreatic cancer after curative resection: A retrospective single center study. In Vivo 33(6): 2071-2078, 2019. PMID: 31662540. DOI: 10.21873/invivo.11706
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Rits IA
    : Declaration of helsinki. Recommendations guidings doctors in clinical research. World Med J 11: 281, 1964. PMID: 14182999.
    OpenUrlPubMed
  21. ↵
    1. Rozner MA
    : The american society of anesthesiologists physical status score and risk of perioperative infection. JAMA 275(20): 1544, 1996. PMID: 8622238.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Brierley JD,
    2. Gospodarowicz MK,
    3. Wittekind C
    , editors: UICC TNM Classification of Malignant Tumours. 8th edition. Wiley Blackwell; New York, NY: 2017.
  23. ↵
    1. Forrest LM,
    2. McMillan DC,
    3. McArdle CS,
    4. Angerson WJ,
    5. Dunlop DJ
    : Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 89(6): 1028-1030, 2003. PMID: 12966420. DOI: 10.1038/sj.bjc.6601242
    OpenUrlCrossRefPubMed
    1. Zahorec R
    : Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill (in English, Slovak). Bratisl Lek Listy 102(1): 5-14, 2001. PMID: 11723675.
    OpenUrlPubMed
    1. Josse JM,
    2. Cleghorn MC,
    3. Ramji KM,
    4. Jiang H,
    5. Elnahas A,
    6. Jackson TD,
    7. Okrainec A,
    8. Quereshy FA
    : The neutrophil-to-lymphocyte ratio predicts major perioperative complications in patients undergoing colorectal surgery. Colorectal Dis 18(7): O236-242, 2016. PMID: 27154050. DOI: 10.1111/codi.13373
    OpenUrl
  24. ↵
    1. Miyazaki M,
    2. Yoshitomi H,
    3. Miyakawa S,
    4. Uesaka K,
    5. Unno M,
    6. Endo I,
    7. Ota T,
    8. Ohtsuka M,
    9. Kinoshita H,
    10. Shimada K,
    11. Shimizu H,
    12. Tabata M,
    13. Chijiiwa K,
    14. Nagino M,
    15. Hirano S,
    16. Wakai T,
    17. Wada K,
    18. Isayama H,
    19. Okusaka T,
    20. Tsuyuguchi T,
    21. Fujita N,
    22. Furuse J,
    23. Yamao K,
    24. Murakami K,
    25. Yamazaki H,
    26. Kijima H,
    27. Nakanuma Y,
    28. Yoshida M,
    29. Takayashiki T,
    30. Takada T
    : Clinical practice guidelines for the management of biliary tract cancers 2015: the 2nd English edition. J Hepatobiliary Pancreat Sci 22(4): 249-273, 2015. PMID: 25787274. DOI: 10.1002/jhbp.233
    OpenUrlPubMed
  25. ↵
    1. Takada T
    : Clinical practice guidelines for the management of biliary tract and ampullary carcinomas. J Hepatobiliary Pancreat Surg 15(1): 1, 2008. PMID: 18274837. DOI: 10.1007/s00534-007-1273-y
    OpenUrlPubMed
  26. ↵
    1. Utsumi M,
    2. Aoki H,
    3. Kunitomo T,
    4. Mushiake Y,
    5. Yasuhara I,
    6. Arata T,
    7. Katsuda K,
    8. Tanakaya K,
    9. Takeuchi H
    : Evaluation of surgical treatment for incidental gallbladder carcinoma diagnosed during or after laparoscopic cholecystectomy: single center results. BMC Res Notes 10(1): 56, 2017. PMID: 28109315. DOI: 10.1186/s13104-017-2387-1
    OpenUrl
  27. ↵
    1. Clavien PA,
    2. Barkun J,
    3. de Oliveira ML,
    4. Vauthey JN,
    5. Dindo D,
    6. Schulick RD,
    7. de Santibañes E,
    8. Pekolj J,
    9. Slankamenac K,
    10. Bassi C,
    11. Graf R,
    12. Vonlanthen R,
    13. Padbury R,
    14. Cameron JL,
    15. Makuuchi M
    : The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 250(2): 187-196, 2009. PMID: 19638912. DOI: 10.1097/SLA.0b013e3181b13ca2
    OpenUrlCrossRefPubMed
  28. ↵
    1. Youden WJ
    : Index for rating diagnostic tests: Cancer 3(1): 32-35, 1950. PMID: 15405679. DOI: 10.1002/1097-0142(1950)3: 1<32::aid-cncr2820030106>3.0.co;2-3
    OpenUrlCrossRefPubMed
  29. ↵
    1. Kinoshita A,
    2. Onoda H,
    3. Imai N,
    4. Iwaku A,
    5. Oishi M,
    6. Tanaka K,
    7. Fushiya N,
    8. Koike K,
    9. Nishino H,
    10. Matsushima M,
    11. Saeki C,
    12. Tajiri H
    : The Glasgow Prognostic Score, an inflammation based prognostic score, predicts survival in patients with hepatocellular carcinoma. BMC Cancer 13: 52, 2013. PMID: 23374755. DOI: 10.1186/1471-2407-13-52
    OpenUrl
  30. ↵
    1. Wu XS,
    2. Shi LB,
    3. Li ML,
    4. Ding Q,
    5. Weng H,
    6. Wu WG,
    7. Cao Y,
    8. Bao RF,
    9. Shu YJ,
    10. Ding QC,
    11. Mu JS,
    12. Gu J,
    13. Dong P,
    14. Liu YB
    : Evaluation of two inflammation-based prognostic scores in patients with resectable gallbladder carcinoma. Ann Surg Oncol 21(2): 449-457, 2014. PMID: 24081806. DOI: 10.1245/s10434-013-3292-z
    OpenUrlCrossRefPubMed
  31. ↵
    1. Qian BZ,
    2. Li J,
    3. Zhang H,
    4. Kitamura T,
    5. Zhang J,
    6. Campion LR,
    7. Kaiser EA,
    8. Snyder LA,
    9. Pollard JW
    : CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475(7355): 222-225, 2011. PMID: 21654748. DOI: 10.1038/nature10138
    OpenUrlCrossRefPubMed
    1. Coussens LM,
    2. Werb Z
    : Inflammation and cancer. Nature 420(6917): 860-867, 2002. PMID: 12490959. DOI: 10.1038/nature01322
    OpenUrlCrossRefPubMed
  32. ↵
    1. Mantovani A
    : Cancer: Inflaming metastasis. Nature 457(7225): 36-37, 2009. PMID: 19122629. DOI: 10.1038/457036b
    OpenUrlCrossRefPubMed
  33. ↵
    1. Wong VK,
    2. Malik HZ,
    3. Hamady ZZ,
    4. Al-Mukhtar A,
    5. Gomez D,
    6. Prasad KR,
    7. Toogood GJ,
    8. Lodge JP
    : C-reactive protein as a predictor of prognosis following curative resection for colorectal liver metastases. Br J Cancer 96(2): 222-225, 2007. PMID: 17211465. DOI:10.1038/sj.bjc.6603558
    OpenUrlCrossRefPubMed
  34. ↵
    1. Xavier P,
    2. Belo L,
    3. Beires J,
    4. Rebelo I,
    5. Martinez-de-Oliveira J,
    6. Lunet N,
    7. Barros H
    : Serum levels of VEGF and TNF-alpha and their association with C-reactive protein in patients with endometriosis. Arch Gynecol Obstet 273(4): 227-231, 2006. PMID: 16208475. DOI: 10.1007/s00404-005-0080-4 ·
    OpenUrlCrossRefPubMed
  35. ↵
    1. Fondevila C,
    2. Metges JP,
    3. Fuster J,
    4. Grau JJ,
    5. Palacín A,
    6. Castells A,
    7. Volant A,
    8. Pera M
    : p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer 90(1): 206-215, 2004. PMID: 14710231. DOI: 10.1038/sj.bjc.6601455
    OpenUrlCrossRefPubMed
  36. ↵
    1. Valenzuela-Landaeta K,
    2. Rojas P,
    3. Basfi-fer K
    : [Nutritional assessment for cancer patient]. Nutr Hosp 27(2): 516-523, 2012. PMID: 22732977. DOI: 10.1590/S0212-16112012000200025
    OpenUrlPubMed
  37. ↵
    1. McMillan DC,
    2. Elahi MM,
    3. Sattar N,
    4. Angerson WJ,
    5. Johnstone J,
    6. McArdle CS
    : Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer 41(1-2): 64-69, 2001. PMID:12094630 DOI:10.1080/01635581.2001.9680613
    OpenUrlCrossRefPubMed
  38. ↵
    1. Bozzetti F,
    2. Mariani L
    : Perioperative nutritional support of patients undergoing pancreatic surgery in the age of ERAS. Nutrition 30: 1267-1271, 2014. PMID: 24973198. DOI: 10.1016/j.nut.2014.03.002
    OpenUrl
  39. ↵
    1. Uno H,
    2. Furukawa K,
    3. Suzuki D,
    4. Shimizu H,
    5. Ohtsuka M,
    6. Kato A,
    7. Yoshitomi H,
    8. Miyazaki M
    : Immunonutrition suppresses acute inflammatory responses through modulation of resolvin E1 in patients undergoing major hepatobiliary resection. Surgery 160(1): 228-236, 2016. PMID: 26965712. DOI: 10.1016/j.surg. 2016.01.019
    OpenUrl
PreviousNext
Back to top

In this issue

In Vivo: 34 (4)
In Vivo
Vol. 34, Issue 4
July-August 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on In Vivo.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Preoperative C-Reactive Protein/Albumin Ratio as a Predictive Factor for Gallbladder Carcinoma
(Your Name) has sent you a message from In Vivo
(Your Name) thought you would like to see the In Vivo web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
8 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Preoperative C-Reactive Protein/Albumin Ratio as a Predictive Factor for Gallbladder Carcinoma
MASASHI UTSUMI, HIDEKI AOKI, SEICHI NAGAHISA, SEITARO NISHIMURA, YUTA UNE, YUJI KIMURA, MEGUMI WATANABE, FUMITAKA TANIGUCHI, TAKASHI ARATA, KOH KATSUDA, KOHJI TANAKAYA
In Vivo Jul 2020, 34 (4) 1901-1908; DOI: 10.21873/invivo.11986

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Preoperative C-Reactive Protein/Albumin Ratio as a Predictive Factor for Gallbladder Carcinoma
MASASHI UTSUMI, HIDEKI AOKI, SEICHI NAGAHISA, SEITARO NISHIMURA, YUTA UNE, YUJI KIMURA, MEGUMI WATANABE, FUMITAKA TANIGUCHI, TAKASHI ARATA, KOH KATSUDA, KOHJI TANAKAYA
In Vivo Jul 2020, 34 (4) 1901-1908; DOI: 10.21873/invivo.11986
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Comparison of Inflammation-based Prognostic Scores in Patients With Biliary Tract Cancer After Surgical Resection
  • Google Scholar

More in this TOC Section

  • Immunostimulation and Coagulopathy in COVID-19 Compared to Patients With H1N1 Pneumonia or Bacterial Sepsis
  • Clinical Application Study of Semi-cylindrical Beam Spoiler for Radiation Treatment of Early-stage Glottic Cancer Patients
  • Supportive Oligonucleotide Therapy (SOT) as an Alternative Treatment Option in Cancer: A Preliminary Study
Show more Clinical Studies

Similar Articles

Keywords

  • C-reactive protein to albumin ratio
  • gallbladder carcinoma
  • Inflammation-based prognostic score
In Vivo

© 2022 In Vivo

Powered by HighWire